Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface

Area of Science:

• Cardiovascular medicine
• Molecular biology
• Pharmacology

Background:

• Pathological stress from cardiovascular disease induces cardiac hypertrophy, a condition escalating risks of cardiac morbidity and mortality.
• Current therapies targeting extracellular signaling pathways for antihypertrophic effects exhibit limited efficacy.
• Emerging research highlights the potential of targeting intracellular signaling pathways within cardiac cells.

Purpose of the Study:

• To review recent advancements in small-molecule inhibitors for cardiac hypertrophy.
• To discuss therapeutic agents currently in or nearing clinical trials.
• To identify promising intracellular pathways as future drug targets.

Main Methods:

• Literature review of recent studies on cardiac hypertrophy inhibitors.
• Analysis of small-molecule agents targeting intracellular signaling pathways.
• Evaluation of pathways with therapeutic potential for cardiac hypertrophy.

Main Results:

• Several small-molecule inhibitors targeting intracellular pathways are under investigation.
• Some agents are progressing towards or are in clinical testing phases.
• Specific intracellular pathways have been identified as promising targets for future drug development.

Conclusions:

• Targeting intracellular signaling pathways with small-molecule inhibitors represents a promising strategy for managing cardiac hypertrophy.
• Further research and development of these agents could lead to improved treatments for cardiovascular disease-related cardiac conditions.
• Identifying and validating novel intracellular targets are crucial for advancing antihypertrophic therapies.